NCT01170091已完成不适用
Safety and Effect of Mirapex(Pramipexole) Tablet Among Korean RLS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 651
- 试验地点
- 36
- 主要终点
- Number of Reported Adverse Events
研究概览
简要总结
Safety and Effect of Mirapex(Pramipexole) tablet among Korean Restless Legs Syndrome Patients: An Open-Label, Postmarketing Surveillance Study
详细描述
Study Design:
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Number of Reported Adverse Events
时间窗: Up to 4 weeks
If there is a dose titration, another 4 weeks should be followed up
次要结局
- International Restless Legs Syndrome Rating Scale (IRLS) Change After 4 Weeks of Mirapex Treatment(before and after the treatment with Mirapex (at least 4 weeks after the end of titration))
- Patient-Global Impressions (PGI-I)(before and after the treatment with Mirapex (at least 4 weeks after the end of titration))
- Clinical Global Impressions-Global Improvement (CGI-I)(before and after the treatment with Mirapex (at least 4 weeks after the end of titration))
研究者
研究点 (36)
Loading locations...
相似试验
终止
2 期
Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUDSleep DisorderRestless Legs SyndromeOpioid-use DisorderOpioid WithdrawalNCT04759703Massachusetts General Hospital75
已完成
3 期
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs SyndromeRestless Legs SyndromeNCT00144209Boehringer Ingelheim58
已完成
不适用
Non-interventional Observational Study of Pramipexole in Restless Legs Syndrome: Impact on Quality of LifeRestless Legs SyndromeNCT00539461Boehringer Ingelheim2,023
已完成
3 期
Pramipexole Conversion to Ropinirole Controlled Release (CR)Parkinson DiseaseNCT00275275Rajesh Pahwa, MD61
Unknown
4 期
Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)Parkinson's DiseaseNCT01515774Seoul National University Hospital200